

GRIA3 RABBIT PAB

货号: S222238

产品全名: GRIA3 兔多抗

基因符号: GLUR3; GLURC; GluA3; MRX94; GLUR-C; GLUR-K3

UNIPROT ID: P42263 (Gene Accession - NP_000819)

背景: Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes composed of multiple subunits, arranged to form ligand-gated ion channels. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. The subunit encoded by this gene belongs to a family of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate)-sensitive glutamate receptors, and is subject to RNA editing (AGA->GGA; R->G). Alternative splicing at this locus results in different isoforms, which may vary in their signal transduction properties.

抗原: Synthetic peptide of human GRIA3

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-100; ELISA: 500-1000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction, Neuroscience


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human thyroid cancer using 222238(GRIA3 Antibody) at a dilution of 1/20(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer is first treated with the synthetic peptide and then with 222238(Anti-GRIA3 Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer using 222238(Anti-GRIA3 Antibody) at a dilution of 1/20.



In comparison with the IHC on the left, the same paraffin-embedded Human ovarian cancer is first treated with synthetic peptide and then with D264265(Anti-GRIA3 Antibody) at dilution 1/20.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
